{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:35:23Z","timestamp":1790271323554,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-03715-5","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T20:02:32Z","timestamp":1707768152000},"page":"412-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9642-4649","authenticated-orcid":false,"given":"L.","family":"Barana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nelva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Scivetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. G.","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"3715_CR1","doi-asserted-by":"crossref","unstructured":"F. Kanwal, J.H. Shubrook, Z. Younossi, Y. Natarajan, E. Bugianesi, M.E. Rinella, et al. Preparing for the NASH epidemic: A call to action. Metabolism. 122, 154822 (2021)","DOI":"10.1016\/j.metabol.2021.154822"},{"key":"3715_CR2","doi-asserted-by":"crossref","unstructured":"A.M. Moon, A.G. Singal, E.B. Tapper, Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin. Gastroenterol. Hepatol. 18, 2650\u20132666 (2020).","DOI":"10.1016\/j.cgh.2019.07.060"},{"key":"3715_CR3","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"E.E. Powell, V.W.S. Wong, M. Rinella, Non-alcoholic fatty liver disease. Lancet 397, 2212\u20132224 (2021)","journal-title":"Lancet"},{"issue":"4","key":"3715_CR4","doi-asserted-by":"publisher","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","volume":"17","author":"H Jarvis","year":"2020","unstructured":"H. Jarvis, D. Craig, R. Barker et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med 17(4), e1003100 (2020). https:\/\/doi.org\/10.1371\/journal.pmed.1003100","journal-title":"PLoS Med"},{"key":"3715_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","volume":"68","author":"D Schuppan","year":"2018","unstructured":"D. Schuppan, R. Surabattula, X.Y. Wang, Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68, 238\u2013250 (2018)","journal-title":"J. Hepatol."},{"key":"3715_CR6","first-page":"2672","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Z. Younossi, F. Tacke, M. Arrese, B. Chander Sharma, I. Mostafa, E. Bugianesi et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatol. John Wiley Sons Inc. 69, 2672\u20132682 (2019)","journal-title":"Hepatol. John Wiley Sons Inc."},{"issue":"4","key":"3715_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Z.M. Younossi, P. Golabi, L. de Avila, J.M. Paik, M. Srishord, N. Fukui et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 71(4), 793\u2013801 (2019)","journal-title":"J. Hepatol."},{"issue":"2","key":"3715_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21037\/hbsn.2019.10.21","volume":"9","author":"G Targher","year":"2020","unstructured":"G. Targher, Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus? Hepatobiliary Surg. Nutr. 9(2), 239\u2013241 (2020)","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"3715_CR9","doi-asserted-by":"crossref","unstructured":"G. Targher, L. Bertolini, F. Poli, S. Rodella, L. Scala, R. Tessari, et al. Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients. Diabetes 54, (2005). Available from: http:\/\/diabetesjournals.org\/diabetes\/article-pdf\/54\/12\/3541\/379333\/zdb01205003541.pdf","DOI":"10.2337\/diabetes.54.12.3541"},{"issue":"3","key":"3715_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/liv.13994","volume":"39","author":"AE Morrison","year":"2019","unstructured":"A.E. Morrison, F. Zaccardi, K. Khunti, M.J. Davies, Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis. Liver Int. 39(3), 557\u2013567 (2019)","journal-title":"Liver Int."},{"key":"3715_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","volume":"68","author":"A Lonardo","year":"2018","unstructured":"A. Lonardo, F. Nascimbeni, A. Mantovani, G. Targher, Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J. Hepatol. 68, 335\u2013352 (2018)","journal-title":"J. Hepatol."},{"issue":"8","key":"3715_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"E. Buzzetti, M. Pinzani, E.A. Tsochatzis, The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65(8), 1038\u20131048 (2016)","journal-title":"Metabolism"},{"key":"3715_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"M. Eslam, P.N. Newsome, S.K. Sarin, Q.M. Anstee, G. Targher, M. Romero-Gomez et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73, 202\u2013209 (2020)","journal-title":"J. Hepatol."},{"key":"3715_CR14","doi-asserted-by":"crossref","unstructured":"N.A. ElSayed, G. Aleppo, V.R. Aroda, R.R. Bannuru, F.M. Brown, D. Bruemmer et al. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes\u20142023. Diabetes Care 46(Supplement_1), S49\u2013S67 (2023). https:\/\/diabetesjournals.org\/care\/article\/46\/Supplement_1\/S49\/148058\/4-Comprehensive-Medical-Evaluation-and-Assessment","DOI":"10.2337\/dc23-er09a"},{"key":"3715_CR15","doi-asserted-by":"crossref","unstructured":"S. Ciardullo, E. Muraca, S. Perra, E. Bianconi, F. Zerbini, A. Oltolini et al. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diab Res Care 8, 904 (2020). http:\/\/drc.bmj.com\/","DOI":"10.1136\/bmjdrc-2019-000904"},{"issue":"6","key":"3715_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"G Marchesini","year":"2016","unstructured":"G. Marchesini, C.P. Day, J.F. Dufour, A. Canbay, V. Nobili, V. Ratziu et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64(6), 1388\u20131402 (2016). Jun 1","journal-title":"J. Hepatol."},{"issue":"1","key":"3715_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1148\/radiol.14140828","volume":"275","author":"J Zheng","year":"2015","unstructured":"J. Zheng, H. Guo, J. Zeng, Z. Huang, B. Zheng, J. Ren et al. Two-dimensional shear-wave elastography and conventional us: The optimal evaluation of liver fibrosis and cirrhosis. Radiology 275(1), 290\u2013300 (2015)","journal-title":"Radiology"},{"key":"3715_CR18","doi-asserted-by":"crossref","unstructured":"K. Koz\u0142owska-Petriczko, E. Wunsch, J. Petriczko, W.K. Syn, P. Milkiewicz. Diagnostic accuracy of non-imaging and ultrasound-based assessment of hepatic steatosis using controlled attenuation parameter (Cap) as reference. J Clin Med. 10(7) 1507 (2021)","DOI":"10.3390\/jcm10071507"},{"key":"3715_CR19","first-page":"1264","volume":"156","author":"L Castera","year":"2019","unstructured":"L. Castera, M. Friedrich-Rust, R. Loomba, Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterol. W. B. Saunders 156, 1264\u20131281.e4 (2019)","journal-title":"Gastroenterol. W. B. Saunders"},{"issue":"24","key":"3715_CR20","doi-asserted-by":"publisher","first-page":"e150996","DOI":"10.1172\/JCI150996","volume":"131","author":"CC Cohen","year":"2021","unstructured":"C.C. Cohen, K.W. Li, A.L. Alazraki et al. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease. J. Clin. Invest. 131(24), e150996 (2021). https:\/\/doi.org\/10.1172\/JCI150996","journal-title":"J. Clin. Invest."},{"key":"3715_CR21","unstructured":"E. Reginato, R. Pippi, C. Aiello, E.S. Tomaro, C. Ranucci, L. Buratta et al. Clinical Medicine Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and\/or Type 2 Diabetes. Available from: www.mdpi.com\/journal\/jcm"},{"issue":"7","key":"3715_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1701\/2318.24928","volume":"107","author":"E Bugianesi","year":"2016","unstructured":"E. Bugianesi, M. Marietti, Non-alcoholic fatty liver disease (NAFLD). Recent. Prog. Med 107(7), 360\u2013368 (2016). https:\/\/doi.org\/10.1701\/2318.24928","journal-title":"Recent. Prog. Med"},{"issue":"2","key":"3715_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"E. Vilar-Gomez, Y. Martinez-Perez, L. Calzadilla-Bertot, A. Torres-Gonzalez, B. Gra-Oramas, L. Gonzalez-Fabian et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149(2), 367\u2013378.e5 (2015)","journal-title":"Gastroenterology"},{"key":"3715_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cts.12839","volume":"14","author":"SL Attia","year":"2021","unstructured":"S.L. Attia, S. Softic, M. Mouzaki, Evolving Role for Pharmacotherapy in NAFLD\/NASH. Clin. Transl. Sci. Blackwell Publ. Ltd 14, 11\u201319 (2021)","journal-title":"Clin. Transl. Sci. Blackwell Publ. Ltd"},{"key":"3715_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","volume":"7","author":"A Mantovani","year":"2022","unstructured":"A. Mantovani, C.D. Byrne, G. Targher, Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol. Hepatol. 7, 367\u2013378 (2022)","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"3715_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"G. Targher, K.E. Corey, C.D. Byrne, M. Roden, The complex link between NAFLD and type 2 diabetes mellitus \u2014 mechanisms and treatments. Nat. Rev. Gastroenterol. Hepatol. Nat. Res. 18, 599\u2013612 (2021)","journal-title":"Nat. Rev. Gastroenterol. Hepatol. Nat. Res."},{"issue":"5","key":"3715_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"K. Cusi, S. Isaacs, D. Barb, R. Basu, S. Caprio, W.T. Garvey et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Pract. 28(5), 528\u2013562 (2022)","journal-title":"Endocr. Pract."},{"issue":"2","key":"3715_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2337\/dci19-0064","volume":"43","author":"K Cusi","year":"2020","unstructured":"K. Cusi, Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes. Diabetes Care 43(2), 275\u2013279 (2020)","journal-title":"Diabetes Care"},{"issue":"1","key":"3715_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","volume":"72","author":"JV Lazarus","year":"2020","unstructured":"J.V. Lazarus, M. Ekstedt, G. Marchesini, J. Mullen, K. Novak, J.M. Peric\u00e0s et al. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J. Hepatol. 72(1), 14\u201324 (2020)","journal-title":"J. Hepatol."},{"issue":"5","key":"3715_CR30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00592-021-01677-y","volume":"58","author":"S Ciardullo","year":"2021","unstructured":"S. Ciardullo, T. Monti, G. Perseghin, Lack of awareness of liver organ damage in patients with type 2 diabetes. Acta Diabetologica 58(5), 651\u2013655 (2021). https:\/\/doi.org\/10.1007\/s00592-021-01677-y","journal-title":"Acta Diabetologica"},{"issue":"3","key":"3715_CR31","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jhep.2023.04.035","volume":"79","author":"JV Lazarus","year":"2023","unstructured":"J.V. Lazarus, H.E. Mark, A.M. Allen, J.P. Arab, P. Carrieri, M. Noureddin, W. Alazawi, N. Alkhouri, S.A. Alqahtani, M. Arrese, R. Bataller, T. Berg, P.N. Brennan, P. Burra, G.E. Castro-Narro, H. Cortez-Pinto, K. Cusi, N. Dedes, A. Duseja, S.M. Francque; Healthy Livers, Healthy Lives Collaborators, A global research priority agenda to advance public health responses to fatty liver disease. J. Hepatol. 79(3), 618\u2013634 (2023). https:\/\/doi.org\/10.1016\/j.jhep.2023.04.035","journal-title":"J. Hepatol."},{"key":"3715_CR32","doi-asserted-by":"publisher","unstructured":"Associazione Italiana per lo Studio del Fegato (AISF), Societ\u00e0 Italiana di Diabetologia (SID) and Societ\u00e0 Italiana dell\u2019Obesit\u00e0 (SIO), Members of the guidelines panel, Coordinator, AISF Members, SID Members, SIO Members, & Metodologists, Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Digestive Liver Dis. 54(2), 170\u2013182 (2022). https:\/\/doi.org\/10.1016\/j.dld.2021.04.029","DOI":"10.1016\/j.dld.2021.04.029"},{"issue":"12","key":"3715_CR33","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S2213-8587(22)00278-9","volume":"10","author":"K Khunti","year":"2022","unstructured":"K. Khunti, V.R. Aroda, P. Aschner, J.C.N. Chan, S. Del Prato, C.E. Hambling, S. Harris, R. Lamptey, M. McKee, N. Tandon, J. Valabhji, S. Seidu, The impact of the COVID-19 pandemic on diabetes services: planning for a global recovery. lancet Diabetes Endocrinol. 10(12), 890\u2013900 (2022). https:\/\/doi.org\/10.1016\/S2213-8587(22)00278-9","journal-title":"lancet Diabetes Endocrinol."},{"key":"3715_CR34","doi-asserted-by":"publisher","first-page":"110672","DOI":"10.1016\/j.diabres.2023.110672","volume":"199","author":"G Russo","year":"2023","unstructured":"G. Russo, P. Di Bartolo, R. Candido, G. Lucisano, V. Manicardi, A. Giandalia, A. Nicolucci, A. Rocca, M.C. Rossi, G. Di Cianni; AMD Annals Study Group, The AMD ANNALS: A continuous initiative for the improvement of type 2 diabetes care. Diabetes Res. Clin. Pract. 199, 110672 (2023). https:\/\/doi.org\/10.1016\/j.diabres.2023.110672","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"2","key":"3715_CR35","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2337\/dc20-1778","volume":"44","author":"S Ciardullo","year":"2021","unstructured":"S. Ciardullo, T. Monti, G. Perseghin, High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes. Diabetes Care 44(2), 519\u2013525 (2021). https:\/\/doi.org\/10.2337\/dc20-1778","journal-title":"Diabetes Care"},{"key":"3715_CR36","unstructured":"G. Russo, A. Rocca, V. Manicardi, R. Candido, M. Cavallo, I. Crisci, et al. La steatosi epatica non alcolica (NAFLD) nel diabete di tipo 2 analisi stratificata per et\u00e0, sesso e BMI, 2022"},{"issue":"4","key":"3715_CR37","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.diabet.2019.11.004","volume":"46","author":"A Mantovani","year":"2020","unstructured":"A. Mantovani, T. Turino, M.G. Lando, K. Gjini, C.D. Byrne, C. Zusi et al. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 46(4), 296\u2013303 (2020)","journal-title":"Diabetes Metab."},{"issue":"32","key":"3715_CR38","doi-asserted-by":"publisher","first-page":"9607","DOI":"10.3748\/wjg.v21.i32.9607","volume":"21","author":"WD Li","year":"2015","unstructured":"W.D. Li, K.F. Fu, G.M. Li, Y.S. Lian, A.M. Ren, Y.J. Chen et al. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus. World J. Gastroenterol. 21(32), 9607\u20139613 (2015)","journal-title":"World J. Gastroenterol."},{"key":"3715_CR39","doi-asserted-by":"publisher","unstructured":"J. Park, G. Kim, B.S. Kim, K.D. Han, S. Yoon Kwon, S. Hee Park, et al. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Available from: https:\/\/doi.org\/10.1186\/s12933-022-01483-y","DOI":"10.1186\/s12933-022-01483-y"},{"key":"3715_CR40","doi-asserted-by":"crossref","unstructured":"G. Targher, A. Mantovani, A. Csermely, G. Petracca, G. Beatrice, K.E. Corey et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Diabetes Metabol. 2021. Available from: www.thelancet.com\/gastrohep","DOI":"10.1016\/S2468-1253(21)00308-3"},{"key":"3715_CR41","doi-asserted-by":"crossref","unstructured":"R.S. Taylor, R.J. Taylor, S. Bayliss, H. Hagstr\u00f6m, P. Nasr, J.M. Schattenberg et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology 158(6), 1611\u20131625.e12 (2020). http:\/\/www.gastrojournal.org\/article\/S0016508520301372\/fulltext","DOI":"10.1053\/j.gastro.2020.01.043"},{"issue":"7","key":"3715_CR42","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/ajg.2014.132","volume":"109","author":"G Zoppini","year":"2014","unstructured":"G. Zoppini, U. Fedeli, N. Gennaro, M. Saugo, G. Targher, E. Bonora, Mortality from chronic liver diseases in diabetes. Am. J. Gastroenterol. 109(7), 1020\u20131025 (2014)","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"3715_CR43","doi-asserted-by":"publisher","first-page":"965","DOI":"10.14218\/JCTH.2021.00564","volume":"10","author":"ES Koullias","year":"2022","unstructured":"E.S. Koullias, J. Koskinas, Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2. J. Clin. Transl. Hepatol. 10(5), 965\u2013971 (2022). https:\/\/doi.org\/10.14218\/JCTH.2021.00564","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"5","key":"3715_CR44","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/dom.14650","volume":"24","author":"O Lavynenko","year":"2022","unstructured":"O. Lavynenko, M. Abdul-Ghani, M. Alatrach et al. Combination therapy with pioglitazone\/exenatide\/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes Obes. Metab. 24(5), 899\u2013907 (2022). https:\/\/doi.org\/10.1111\/dom.14650","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"3715_CR45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"A. Gastaldelli, K. Cusi, L. Fern\u00e1ndez Land\u00f3, R. Bray, B. Brouwers, \u00c1. Rodr\u00edguez, Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 10(6), 393\u2013406 (2022). https:\/\/doi.org\/10.1016\/S2213-8587(22)00070-5","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3715_CR46","doi-asserted-by":"publisher","first-page":"768850","DOI":"10.3389\/fendo.2021.768850","volume":"12","author":"K Yabiku","year":"2021","unstructured":"K. Yabiku, Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Front. Endocrinol. 12, 768850 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.768850","journal-title":"Front. Endocrinol."},{"issue":"4","key":"3715_CR47","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00592-021-01830-7","volume":"59","author":"C Ding","year":"2022","unstructured":"C. Ding, Y. Tang, W. Zhu et al. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. Acta Diabetol. 59(4), 519\u2013533 (2022). https:\/\/doi.org\/10.1007\/s00592-021-01830-7","journal-title":"Acta Diabetol."},{"issue":"10","key":"3715_CR48","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.cgh.2020.05.021","volume":"18","author":"JC Hsiang","year":"2020","unstructured":"J.C. Hsiang, V.W. Wong, SGLT2 Inhibitors in Liver Patients. Clin. Gastroen Terol Hepatol. 18(10), 2168\u20132172.e2 (2020). https:\/\/doi.org\/10.1016\/j.cgh.2020.05.021","journal-title":"Clin. Gastroen Terol Hepatol."},{"issue":"6","key":"3715_CR49","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"M.E. Rinella, J.V. Lazarus, V. Ratziu, S.M. Francque, A.J. Sanyal, F. Kanwal, D. Romero, M.F. Abdelmalek, Q.M. Anstee, J.P. Arab, M. Arrese, R. Bataller, U. Beuers, J. Boursier, E. Bugianesi, C.D. Byrne, G.E. Castro Narro, A. Chowdhury, H. Cortez-Pinto, D.R. Cryer; NAFLD Nomenclature consensus group, A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79(6), 1542\u20131556 (2023). https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003","journal-title":"J. Hepatol."},{"key":"3715_CR50","doi-asserted-by":"crossref","unstructured":"K. Bj\u00f6rkstr\u00f6m, P. St\u00e5l, R. Hultcrantz, H. Hagstr\u00f6m, Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 15(9), 1461\u20131468 (2017). http:\/\/www.cghjournal.org\/article\/S1542356517305347\/fulltext","DOI":"10.1016\/j.cgh.2017.04.040"},{"key":"3715_CR51","doi-asserted-by":"crossref","unstructured":"A. Mantovani, G. Petracca, G. Beatrice, H. Tilg, C.D. Byrne, G. Targher, Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 70(5), 962\u2013969 (2021). https:\/\/gut.bmj.com\/content\/70\/5\/962","DOI":"10.1136\/gutjnl-2020-322572"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03715-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03715-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03715-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T06:24:34Z","timestamp":1715063074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03715-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["3715"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03715-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"4 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}